Follicular Challenge Test to Predict Response to GnRH Agonist Triggering

Not Applicable

• Conditions: Infertility, Female

• Registration Number: NCT04973969
• Lead Sponsor: Assaf-Harofeh Medical Center

Brief Summary

GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or suboptimal response was displayed.

The investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.

Detailed Description

The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist protocol.

Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the hormonal profile will be compared to day after ovulation triggering.

Study Timeline

• Study Start: 2021-01-01
• Study First Submitted: 2021-06-13
• Status Verified: 2021-07
• Study First Submitted QC: 2021-07-21
• Last Update Submitted: 2021-07-21
• Study First Posted: 2021-07-22
• Last Update Posted: 2021-07-22
• Primary Completion: 2022-04-30
• Study Completion: 2022-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• patients that undergo fertility preservation

  • patients planned to freeze embryos due to PGT or surrogacy --patients at high risk for OHSS

Exclusion Criteria

• Poor ovarian response
• known hypothalamic- pituitary dysfunction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
The response to GnRH triggering	One treatment cycle (each cycle is 28 days) for each participant (up to 28 days).	LH levels 10-12 hours after decapeptyl trigger, number of mature oocytes

Trial Locations

Locations (1)

Shamir medical center; 🇮🇱 Tzrifin, Israel